Korean Circulation Journal

  • 제42권8호
  • /
  • Pages.513-518
  • /
  • 2012
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Epidemiology and Clinical Management of Pulmonary Hypertension in Children

  • Jin, Hongfang (Department of Pediatrics, Peking University First Hospital) ;
  • Yang, Jinyan (Department of Pediatrics, Peking University First Hospital) ;
  • Zhang, Qingyou (Department of Pediatrics, Peking University First Hospital) ;
  • Du, Junbao (Department of Pediatrics, Peking University First Hospital)
  • 발행 : 2012.08.31
⟨ 이전 논문 다음 논문 ⟩

초록

Pulmonary hypertension (PH) is a clinical hemodynamic syndrome characterized by increased pulmonary artery pressure and pulmonary vascular resistance. It can cause right ventricular failure, and even death. Pediatric PH is not very common, but is a greatly hazardous disease that leads to a high mortality rate. Therefore, many registry organizations have been established in the world to strengthen the study of diagnosis and treatment of the disease, and improve the understanding of pediatric PH. This article reviewed recently published researches, as well as presented a comprehensive understanding of PH, including definition, classification, epidemiology, prognosis and treatment.

키워드

참고문헌

  1. Fasnacht MS, Tolsa JF, Beghetti M; Swiss Society for Pulmonary Arterial Hypertension. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly 2007;137:510-3.
  2. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-7.
  3. Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010;103:66-74. https://doi.org/10.1016/j.acvd.2009.12.001
  4. van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011;124:1755-64. https://doi.org/10.1161/CIRCULATIONAHA.110.969584
  5. Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537-46. https://doi.org/10.1016/S0140-6736(11)61621-8
  6. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012;125:113-22. https://doi.org/10.1161/CIRCULATIONAHA.111.026591
  7. Zhou AQ, Zhang QY, DU JB. [Research on pulmonary hypertension in children: present and future]. Zhonghua Er Ke Za Zhi 2011;49:881-5.
  8. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66. https://doi.org/10.1016/j.jacc.2009.04.011
  9. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011;37:665-77. https://doi.org/10.1183/09031936.00056110
  10. Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol 2012;27:70-81. https://doi.org/10.1097/HCO.0b013e32835018cd
  11. Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010;106:1332-8. https://doi.org/10.1016/j.amjcard.2010.06.064
  12. Fu LJ, Zhou AQ, Guo Y, Zhao PJ, Huang MR, Li F. [Adenosine for pulmonary vasodilator testing in children with idiopathic pulmonary arterial hypertension]. Zhonghua Er Ke Za Zhi 2011;49:886-9.
  13. Zhang QY, Du JB. Progress on treatment or pulmonary hypertension in children. J Clin Pediatr 2010;28:607-10.
  14. Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010;157:528-32. https://doi.org/10.1016/j.jpeds.2010.06.010
  15. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110:660-5. https://doi.org/10.1161/01.CIR.0000138104.83366.E9
  16. Simonneau G, Barst RJ, Gaile N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4. https://doi.org/10.1164/ajrccm.165.6.2106079
  17. Rosenzweig EB, Krishnan U, Takatsuki S, Kerstein J, Calderbank M, Ivy DD. Inhaled treprostinil in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;183:A6143.
  18. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:161-9. https://doi.org/10.1016/j.jacc.2007.09.031
  19. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358: 1119-23. https://doi.org/10.1016/S0140-6736(01)06250-X
  20. Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 2006;25:469-73. https://doi.org/10.1016/j.healun.2005.11.438
  21. Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Longterm efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011;38:70-7. https://doi.org/10.1183/09031936.00053510
  22. Xu ZM, Zhu LM, Cai XM, Ji G, Liu JF, Su ZK. [Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi 2009;89:2106-9.
  23. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007;154:776-82. https://doi.org/10.1016/j.ahj.2007.06.003
  24. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008;64:200-4. https://doi.org/10.1203/PDR.0b013e318179954c
  25. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84, 384.e1-2.
  26. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebocontrolled, dose-ranging study of oral sildenafil citrate in treatmentnaive children with pulmonary arterial hypertension. Circulation 2012; 125:324-34. https://doi.org/10.1161/CIRCULATIONAHA.110.016667
  27. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011;108:1177-82. https://doi.org/10.1016/j.amjcard.2011.06.021

피인용 문헌

  1. Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art vol.7, pp.None, 2012, https://doi.org/10.3389/fped.2019.00302